Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06550895 · ClinicalTrials.gov registry record · Phase 2
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 9
- Study locations
NCT06550895 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 11 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT06550895, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
Conditions Studied
Interventions
- DRUG Cilta-cel
- DRUG Talquetamab
Study Locations (9)
Other
- Royal Prince Alfred Hospital - Camperdown
- Austin Hospital - Heidelberg
- Peter MacCallum Cancer Centre - Melbourne
- The Alfred Hospital - Melbourne
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Kentucky
- Norton Cancer Institute - Louisville
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
New York
- Icahn School of Medicine at Mount Sinai - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2027-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06550895
The ClinicalTrials.gov registry entry for NCT06550895 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Cilta-cel is the first listed.
NCT06550895 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Other, Iowa, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06550895 about?
NCT06550895 is a clinical study titled "A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma". The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
What is the current status of trial NCT06550895?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2024-09-16. Estimated completion is 2027-08-26.
What conditions does trial NCT06550895 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06550895?
The interventions under investigation include: Cilta-cel (DRUG), Talquetamab (DRUG).
Who is sponsoring clinical trial NCT06550895?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06550895 being conducted?
This trial has 9 study locations across Iowa, Kentucky, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.